LEGISLATURE OF NEBRASKA

ONE HUNDRED THIRD LEGISLATURE

SECOND SESSION

LEGISLATIVE BILL 1102

Introduced by Crawford, 45; Chambers, 11; Davis, 43; Garrett, 3; Wallman, 30.

Read first time January 22, 2014

Committee:

A BILL

1	FOR AN ACT	relating to the Uniform Controlled Substances Act; to
2		amend section 28-401.01, Revised Statutes Cumulative
3		Supplement, 2012, and section 28-401, Revised Statutes
4		Supplement, 2013; to adopt Will's Law; to redefine
5		marijuana and authorize the medical use of hemp oil
6		extract which contains no more than three-tenths of one
7		percent tetrahydrocannabinols; to harmonize provisions;
8		and to repeal the original sections.

1 Section 1. Section 28-401, Revised Statutes Supplement,

- 2 2013, is amended to read:
- 3 28-401 As used in the Uniform Controlled Substances Act,
- 4 unless the context otherwise requires:
- 5 (1) Administer shall mean to directly apply a controlled
- 6 substance by injection, inhalation, ingestion, or any other means to
- 7 the body of a patient or research subject;
- 8 (2) Agent shall mean an authorized person who acts on
- 9 behalf of or at the direction of another person but shall not include
- 10 a common or contract carrier, public warehouse keeper, or employee of
- 11 a carrier or warehouse keeper;
- 12 (3) Administration shall mean the Drug Enforcement
- 13 Administration, United States Department of Justice;
- 14 (4) Controlled substance shall mean a drug, biological,
- 15 substance, or immediate precursor in Schedules I to V of section
- 16 28-405. Controlled substance shall not include distilled spirits,
- 17 wine, malt beverages, tobacco, or any nonnarcotic substance if such
- 18 substance may, under the Federal Food, Drug, and Cosmetic Act, 21
- 19 U.S.C. 301 et seq., as such act existed on January 1, 2009, and the
- 20 law of this state, be lawfully sold over the counter without a
- 21 prescription;
- 22 (5) Counterfeit substance shall mean a controlled
- 23 substance which, or the container or labeling of which, without
- 24 authorization, bears the trademark, trade name, or other identifying
- 25 mark, imprint, number, or device, or any likeness thereof, of a

1 manufacturer, distributor, or dispenser other than the person or

- 2 persons who in fact manufactured, distributed, or dispensed such
- 3 substance and which thereby falsely purports or is represented to be
- 4 the product of, or to have been distributed by, such other
- 5 manufacturer, distributor, or dispenser;
- 6 (6) Department shall mean the Department of Health and
- 7 Human Services;
- 8 (7) Division of Drug Control shall mean the personnel of
- 9 the Nebraska State Patrol who are assigned to enforce the Uniform
- 10 Controlled Substances Act;
- 11 (8) Dispense shall mean to deliver a controlled substance
- 12 to an ultimate user or a research subject pursuant to a medical order
- 13 issued by a practitioner authorized to prescribe, including the
- 14 packaging, labeling, or compounding necessary to prepare the
- 15 controlled substance for such delivery;
- 16 (9) Distribute shall mean to deliver other than by
- 17 administering or dispensing a controlled substance;
- 18 (10) Prescribe shall mean to issue a medical order;
- 19 (11) Drug shall mean (a) articles recognized in the
- 20 official United States Pharmacopoeia, official Homeopathic
- 21 Pharmacopoeia of the United States, official National Formulary, or
- 22 any supplement to any of them, (b) substances intended for use in the
- 23 diagnosis, cure, mitigation, treatment, or prevention of disease in
- 24 human beings or animals, and (c) substances intended for use as a
- 25 component of any article specified in subdivision (a) or (b) of this

LB 1102 LB 1102

1 subdivision, but shall not include devices or their components,

- 2 parts, or accessories;
- 3 (12) Deliver or delivery shall mean the actual,
- 4 constructive, or attempted transfer from one person to another of a
- 5 controlled substance, whether or not there is an agency relationship;
- 6 (13) Marijuana shall mean all parts of the plant of the
- 7 genus cannabis, whether growing or not, the seeds thereof, and every
- 8 compound, manufacture, salt, derivative, mixture, or preparation of
- 9 such plant or its seeds, but shall not include the mature stalks of
- 10 such plant, hashish, tetrahydrocannabinols extracted or isolated from
- 11 the plant, fiber produced from such stalks, oil or cake made from the
- 12 seeds of such plant, any other compound, manufacture, salt,
- 13 derivative, mixture, or preparation of such mature stalks, or the
- 14 sterilized seed of such plant which is incapable of germination, or
- 15 any hemp oil extract used or possessed pursuant to section 2 of this
- 16 <u>act</u>. When the weight of marijuana is referred to in the Uniform
- 17 Controlled Substances Act, it shall mean its weight at or about the
- 18 time it is seized or otherwise comes into the possession of law
- 19 enforcement authorities, whether cured or uncured at that time;
- 20 (14) Manufacture shall mean the production, preparation,
- 21 propagation, conversion, or processing of a controlled substance,
- 22 either directly or indirectly, by extraction from substances of
- 23 natural origin, independently by means of chemical synthesis, or by a
- 24 combination of extraction and chemical synthesis, and shall include
- 25 any packaging or repackaging of the substance or labeling or

relabeling of its container. Manufacture shall not include the 1 2 preparation or compounding of a controlled substance by an individual 3 for his or her own use, except for the preparation or compounding of components or ingredients used for or intended to be used for the 4 5 manufacture of methamphetamine, or the preparation, compounding, conversion, packaging, or labeling of a controlled substance: (a) By 6 7 a practitioner as an incident to his or her prescribing, 8 administering, or dispensing of a controlled substance in the course 9 of his or her professional practice; or (b) by a practitioner, or by his or her authorized agent under his or her supervision, for the 10 purpose of, or as an incident to, research, teaching, or chemical 11 12 analysis and not for sale; 13 (15) Narcotic drug shall mean any of the following, whether produced directly or indirectly by extraction from substances 14 15 of vegetable origin, independently by means of chemical synthesis, or by a combination of extraction and chemical synthesis: (a) Opium, 16 opium poppy and poppy straw, coca leaves, and opiates; (b) a 17 compound, manufacture, salt, derivative, or preparation of opium, 18 coca leaves, or opiates; or (c) a substance and any compound, 19 20 manufacture, salt, derivative, or preparation thereof which is chemically equivalent to or identical with any of the substances 21 referred to in subdivisions (a) and (b) of this subdivision, except 22 23 that the words narcotic drug as used in the Uniform Controlled Substances Act shall not include decocainized coca leaves or extracts 24 of coca leaves, which extracts do not contain cocaine or ecgonine, or 25

- 1 isoquinoline alkaloids of opium;
- 2 (16) Opiate shall mean any substance having an addiction-
- 3 forming or addiction-sustaining liability similar to morphine or
- 4 being capable of conversion into a drug having such addiction-forming
- 5 or addiction-sustaining liability. Opiate shall not include the
- 6 dextrorotatory isomer of 3-methoxy-n methylmorphinan and its salts.
- 7 Opiate shall include its racemic and levorotatory forms;
- 8 (17) Opium poppy shall mean the plant of the species
- 9 Papaver somniferum L., except the seeds thereof;
- 10 (18) Poppy straw shall mean all parts, except the seeds,
- of the opium poppy after mowing;
- 12 (19) Person shall mean any corporation, association,
- 13 partnership, limited liability company, or one or more individuals;
- 14 (20) Practitioner shall mean a physician, a physician
- 15 assistant, a dentist, a veterinarian, a pharmacist, a podiatrist, an
- 16 optometrist, a certified nurse midwife, a certified registered nurse
- 17 anesthetist, a nurse practitioner, a scientific investigator, a
- 18 pharmacy, a hospital, or any other person licensed, registered, or
- 19 otherwise permitted to distribute, dispense, prescribe, conduct
- 20 research with respect to, or administer a controlled substance in the
- 21 course of practice or research in this state, including an emergency
- 22 medical service as defined in section 38-1207;
- 23 (21) Production shall include the manufacture, planting,
- 24 cultivation, or harvesting of a controlled substance;
- 25 (22) Immediate precursor shall mean a substance which is

1 the principal compound commonly used or produced primarily for use

- 2 and which is an immediate chemical intermediary used or likely to be
- 3 used in the manufacture of a controlled substance, the control of
- 4 which is necessary to prevent, curtail, or limit such manufacture;
- 5 (23) State shall mean the State of Nebraska;
- 6 (24) Ultimate user shall mean a person who lawfully
- 7 possesses a controlled substance for his or her own use, for the use
- 8 of a member of his or her household, or for administration to an
- 9 animal owned by him or her or by a member of his or her household;
- 10 (25) Hospital shall have the same meaning as in section
- 11 71-419;
- 12 (26) Cooperating individual shall mean any person, other
- 13 than a commissioned law enforcement officer, who acts on behalf of,
- 14 at the request of, or as agent for a law enforcement agency for the
- 15 purpose of gathering or obtaining evidence of offenses punishable
- 16 under the Uniform Controlled Substances Act;
- 17 (27) Hashish or concentrated cannabis shall mean: (a) The
- 18 separated resin, whether crude or purified, obtained from a plant of
- 19 the genus cannabis; or (b) any material, preparation, mixture,
- 20 compound, or other substance which contains ten percent or more by
- 21 weight of tetrahydrocannabinols;
- 22 (28) Exceptionally hazardous drug shall mean (a) a
- 23 narcotic drug, (b) thiophene analog of phencyclidine, (c)
- 24 phencyclidine, (d) amobarbital, (e) secobarbital, (f) pentobarbital,
- 25 (g) amphetamine, or (h) methamphetamine;

LB 1102 LB 1102

1 Imitation controlled substance (29)shall 2 substance which is not a controlled substance but which, by way of 3 express or implied representations and consideration of other relevant factors including those specified in section 28-445, would 4 5 lead a reasonable person to believe the substance is a controlled 6 substance. A placebo or registered investigational drug manufactured, 7 distributed, possessed, or delivered in the ordinary course of 8 practice or research by a health care professional shall not be 9 deemed to be an imitation controlled substance; 10 (30)(a) Controlled substance analogue shall mean a substance (i) the chemical structure of which is substantially 11 12 similar to the chemical structure of a Schedule I or Schedule II 13 controlled substance as provided in section 28-405 or (ii) which has a stimulant, depressant, analgesic, or hallucinogenic effect on the 14 15 central nervous system that is substantially similar to or greater than the stimulant, depressant, analgesic, or hallucinogenic effect 16 on the central nervous system of a Schedule I or Schedule II 17 controlled substance as provided in section 28-405. A controlled 18 19 substance analogue shall, to the extent intended for human 20 consumption, be treated as a controlled substance under Schedule I of 21 section 28-405 for purposes of the Uniform Controlled Substances Act; 22 and 23 (b) Controlled substance analogue shall not include (i) a controlled substance, (ii) any substance generally recognized as safe 24 and effective within the meaning of the Federal Food, Drug, and 25

1 Cosmetic Act, 21 U.S.C. 301 et seq., as such act existed on January

- 2 1, 2009, (iii) any substance for which there is an approved new drug
- 3 application, or (iv) with respect to a particular person, any
- 4 substance if an exemption is in effect for investigational use for
- 5 that person, under section 505 of the Federal Food, Drug, and
- 6 Cosmetic Act, 21 U.S.C. 355, as such section existed on January 1,
- 7 2009, to the extent conduct with respect to such substance is
- 8 pursuant to such exemption;
- 9 (31) Anabolic steroid shall mean any drug or hormonal
- 10 substance, chemically and pharmacologically related to testosterone
- 11 (other than estrogens, progestins, and corticosteroids), that
- 12 promotes muscle growth and includes any controlled substance in
- 13 Schedule III(d) of section 28-405. Anabolic steroid shall not include
- 14 any anabolic steroid which is expressly intended for administration
- 15 through implants to cattle or other nonhuman species and has been
- 16 approved by the Secretary of Health and Human Services for such
- 17 administration, but if any person prescribes, dispenses, or
- 18 distributes such a steroid for human use, such person shall be
- 19 considered to have prescribed, dispensed, or distributed an anabolic
- 20 steroid within the meaning of this subdivision;
- 21 (32) Chart order shall mean an order for a controlled
- 22 substance issued by a practitioner for a patient who is in the
- 23 hospital where the chart is stored or for a patient receiving
- 24 detoxification treatment or maintenance treatment pursuant to section
- 25 28-412. Chart order shall not include a prescription;

1 (33) Medical order shall mean a prescription, a chart

- 2 order, or an order for pharmaceutical care issued by a practitioner;
- 3 (34) Prescription shall mean an order for a controlled
- 4 substance issued by a practitioner. Prescription shall not include a
- 5 chart order;
- 6 (35) Registrant shall mean any person who has a
- 7 controlled substances registration issued by the state or the
- 8 administration;
- 9 (36) Reverse distributor shall mean a person whose
- 10 primary function is to act as an agent for a pharmacy, wholesaler,
- 11 manufacturer, or other entity by receiving, inventorying, and
- 12 managing the disposition of outdated, expired, or otherwise
- 13 nonsaleable controlled substances;
- 14 (37) Signature shall mean the name, word, or mark of a
- 15 person written in his or her own hand with the intent to authenticate
- 16 a writing or other form of communication or a digital signature which
- 17 complies with section 86-611 or an electronic signature;
- 18 (38) Facsimile shall mean a copy generated by a system
- 19 that encodes a document or photograph into electrical signals,
- 20 transmits those signals over telecommunications lines, and
- 21 reconstructs the signals to create an exact duplicate of the original
- 22 document at the receiving end;
- 23 (39) Electronic signature shall have the definition found
- 24 in section 86-621;
- 25 (40) Electronic transmission shall mean transmission of

1 information in electronic form. Electronic transmission may include

- 2 computer-to-computer transmission or computer-to-facsimile
- 3 transmission; and
- 4 (41) Long-term care facility shall mean an intermediate
- 5 care facility, an intermediate care facility for persons with
- 6 developmental disabilities, a long-term care hospital, a mental
- 7 health center, a nursing facility, or a skilled nursing facility, as
- 8 such terms are defined in the Health Care Facility Licensure Act.
- 9 Sec. 2. Section 28-401.01, Revised Statutes Cumulative
- 10 Supplement, 2012, is amended to read:
- 11 28-401.01 Sections 28-401 to 28-456.01 and 28-458 to
- 12 28-462 and section 3 of this act shall be known and may be cited as
- 13 the Uniform Controlled Substances Act.
- Sec. 3. (1) This section shall be known and may be cited
- 15 <u>as Will's Law.</u>
- 16 (2) For purposes of Will's Law:
- 17 (a) Bona fide physician-patient relationship means a
- 18 relationship in which a physician who specializes in the treatment of
- 19 epilepsy and has ongoing responsibility for the assessment, care, and
- 20 treatment of a patient's medical condition;
- 21 (b) Debilitating medical condition means a chronic or
- 22 debilitating disease or medical condition that is not adequately
- 23 treated by traditional medical therapies or the treatment of a
- 24 <u>chronic or debilitating disease or medical condition that produces</u>
- 25 one or more of the following, as documented by a physician with whom

1 the patient has a bona fide physician-patient relationship:

- 2 (i) Seizures; or
- 3 (ii) Severe or persistent muscle spasms; and
- 4 (c) Hemp oil extract means an oil extracted from any part
- 5 of a plant of the genus cannabis, whether growing or not, or the
- 6 seeds thereof, which oil contains a maximum of three-tenths of one
- 7 percent tetrahydrocannabinols by volume.
- 8 (3) It shall not be a violation of the Uniform Controlled
- 9 Substances Act if the defendant used or possessed, or the defendant's
- 10 parent or quardian possessed for the purpose of caring for the
- 11 defendant, hemp oil extract because the defendant or his or her child
- 12 or ward has a debilitating medical condition that has been diagnosed
- 13 by a physician with whom the defendant or his or her child or ward
- 14 has a bona fide physician-patient relationship and the hemp oil
- 15 extract is likely to provide the defendant or his or her child or
- 16 ward with therapeutic or palliative relief from the debilitating
- 17 medical condition.
- 18 Sec. 4. Original section 28-401.01, Revised Statutes
- 19 Cumulative Supplement, 2012, and section 28-401, Revised Statutes
- 20 Supplement, 2013, are repealed.